Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Sep 17 2021

• By Jessica Merrill

Listen to this article

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

blue eye — The market for eye treatments is poised for new competition • Source: Alamy

The US treatment market for wet age-related macular degeneration has been solidly established for a decade, dominated by two powerhouse anti-vascular endothelial growth factor (VEGF) brands: Regeneron Pharmaceuticals, Inc.'s Eylea (aflibercept) and Roche Holding AG's Lucentis (ranibizumab). In the next six months, however, the market is poised for a shakeup with the potential launch of the first biosimilar version of Lucentis in the US and the first bispecific antibody for wet AMD, Roche's faricimab.

Regeneron's top priority is defending its market leadership position in the category with Eylea, the company's top-seller and a high-growth...

More from Sensory

Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Mar 10 2025
• By Alexandra Shimmings
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Acelyrin Belatedly Drops Izokibep In Its Lead Indications
Aug 15 2024
• By Elizabeth Cairns
The group has stopped further development of the IL-17A inhibitor in hidradenitis suppurativa and psoriatic arthritis, and intends to pivot to a thyroid eye disease therapy.
Aldeyra Readies Reproxalap For Dry Eye Refiling After Chamber Study Success
Aug 08 2024
• By Mandy Jackson
The company said earlier this year that it would resubmit reproxalap for US FDA approval before the end of 2024 once it completed another Phase III trial and is eyeing both acute and chronic use.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.